Dr. Alok Kumar, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 685
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME67833
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morton Plant Hospital Clearwater, FL
- Mease Countryside Hospital Safety Harbor, FL
- HCA Florida Bayonet Point Hospital Hudson, FL
- HCA Florida Trinity Hospital Trinity, FL
- Morton Plant North Bay Hospital New Port Richey, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 685
- Services billed
- 2,762
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,012 | 204 |
| Established patient office or other outpatient visit, 20-29 minutes | 898 | 413 |
| Established patient office or other outpatient visit, 30-39 minutes | 353 | 210 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 267 | 148 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 177 | 150 |
| New patient office or other outpatient visit, 45-59 minutes | 82 | 82 |
| Test to measure expiratory airflow and volume | 60 | 60 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 44 | 41 |
| New patient office or other outpatient visit, 30-44 minutes | 40 | 40 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 28 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in New Port Richey, FL | 717 |
| Prednisone Other prescribers in New Port Richey, FL | 604 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in New Port Richey, FL | 514 |
| Montelukast Sodium Other prescribers in New Port Richey, FL | 278 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in New Port Richey, FL | 203 |
| Ipratropium Bromide Other prescribers in New Port Richey, FL | 181 |
| Cefuroxime (cefuroxime axetil) Other prescribers in New Port Richey, FL | 154 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in New Port Richey, FL | 148 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in New Port Richey, FL | 146 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in New Port Richey, FL | 135 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 32 payments worth $1,057 in total to this clinician.
| Inspire Medical Systems, Inc. | $308 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $176 |
| GlaxoSmithKline, LLC. | $162 |
| AstraZeneca Pharmaceuticals LP | $151 |
| Insmed, Inc. | $104 |
| Genzyme Corporation | $49.23 |
| Vanda Pharmaceuticals Inc. | $37.82 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27.20 |
| Food and Beverage | $967 |
|---|---|
| Education | $89.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Jul 24, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $89.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $700 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.